Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
3338 Results for "
properties
" in MedChemExpress (MCE) Product Catalog:
Products (3338)
3338 Results for "properties" in MCE Product Catalog:
Cat. No.: HY-163099
CAS No.: 2928571-43-9
Research Areas:
P5 (PEG24)-VC-PAB-Exatecan is a TOP1 inhibitor payload with antibody-conjugation-dependent activity. Conjugation of P5 (PEG24)-VC-PAB-Exatecan with Trastuzumab (HY-P9907) generates a DAR8 antibody-drug conjugate (ADCs) with antibody-like pharmacokinetic properties. P5 (PEG24)-VC-PAB-Exatecan induces S-phase and G2-M-phase cell cycle arrest, DNA damage and apoptosis in target-positive tumor cells, and releases damage-associated molecular patterns (DAMP) related to immunogenic cell death (ICD). The ADCs prepared from it exert bystander killing effects on non-target tumor cells. ADCs based on P5 (PEG24)-VC-PAB-Exatecan exhibit linker stability in vitro and in vivo, show in vivo efficacy, and can be used in research related to HER2-positive cancers .
Cat. No.: HY-164429
CAS No.: 2418533-90-9
VIP236 is a small-molecule drug conjugate targeting αvβ3 integrin. VIP236 achieves tumor homing via specific binding to αvβ3 integrin and delivers its payload to the tumor microenvironment. The linker of VIP236 is cleavable by neutrophil elastase, which is highly expressed in the tumor microenvironment, to release the payload 7-ethylcamptothecin. This payload induces DNA damage by inhibiting topoisomerase 1, thereby exerting anti-tumor effects. VIP236 exhibits excellent plasma stability and tumor targeting property, with a tumor/plasma payload ratio 10-fold higher than that of the single administration. It effectively induces tumor regression, reduces metastasis formation, and shows good tolerance in mouse models. VIP236 has been used in studies related to non-small cell lung cancer, clear cell renal cell carcinoma, colon cancer, triple-negative breast cancer, small cell lung cancer, and metastatic solid tumors .
Cat. No.: HY-169798
CAS No.: 23481-50-7
Target:
Research Areas:
1,9-Dimethylmethylene blue is a photosensitizer, virus inactivator and hemoglobin oxidant derived from methylene blue. When activated, 1,9-Dimethylmethylene blue generates reactive oxygen species including singlet oxygen, and acts as a metachromatic dye. When activated in monomeric or dimeric form, 1,9-Dimethylmethylene blue induces photoinactivation of R17 phage and vesicular stomatitis virus and oxidizes hemoglobin via non-singlet oxygen reactive oxygen species or singlet oxygen-mediated pathways, respectively. The monomeric form, with higher nucleic acid affinity, achieves virus inactivation under specific conditions without forming methemoglobin. 1,9-Dimethylmethylene blue binds to substances such as glycosaminoglycans to produce color changes. Although it is susceptible to interference from non-glycosaminoglycan components in urine, it is still applicable to spectrophotometric analysis for glycosaminoglycan quantification. With these unique photochemical and binding properties, 1,9-Dimethylmethylene blue is widely used in studies of viral infections and related biochemical analyses .
Cat. No.: HY-175991S
Synonyms: Sodium stearyl sulfate sulfate-d37
Cat. No.: HY-182354
CAS No.: 861877-12-5
VEGFR2-IN-84 is an orally active, multi-targeted tyrosine kinase inhibitor based on a naphthalene ring scaffold. VEGFR2-IN-84 inhibits VEGFR2 with sub-nanomolar affinity and broadly targets kinases including Kit, FGFR, PDGFR, and Ret. By competitively binding to the ATP-binding pocket, VEGFR2-IN-84 blocks the phosphorylation of VEGFR2 and its downstream AKT/ERK signaling pathway, thereby significantly inhibiting endothelial cell proliferation, migration, and tumor angiogenesis. VEGFR2-IN-84 exhibits broad-spectrum antiproliferative activity against various solid tumors such as liver cancer, lung cancer, and renal cancer, shows weak toxicity to normal cells, and has superior potency to Lenvatinib (HY-10981). VEGFR2-IN-84 possesses favorable pharmacokinetic properties and high safety (LD50>2000 mg/kg), and can be used in related studies of various malignant tumors .
Synonyms: Citronic acid (Standard); Methylfumaric acid (Standard)
Cat. No.: HY-D3120
CAS No.: 2246946-53-0
Target:
Research Areas:
LysoAIE2 is a Fluorescent probe for lysosomal viscosity detection and live-cell imaging. Its detection mechanism relies on the aggregation-induced emission effect: it exhibits only weak fluorescence in non-viscous media; in viscous environments, restricted intramolecular motion inhibits non-radiative energy dissipation pathways, thereby significantly enhancing fluorescence intensity. It achieves specific targeting of lysosomes through the proton acceptor property of its indole ring structure, while its hydroxyl group endows it with excellent water solubility. This probe is basically unaffected by microenvironmental polarity and pH within the range of pH 4.0 to pH 8.0, which avoids interference from these factors in viscosity measurement. LysoAIE2 has an emission wavelength of 570 nm. It can be used to monitor lysosomal viscosity changes during processes such as Dexamethasone (HY-14648)-induced lysosomal migration and starvation-induced mitophagy in live cells; at concentrations up to 40 μM, cell viability remains above 80%, demonstrating excellent biocompatibility .
Cat. No.: HY-N0565AR
CAS No.: 10592-13-9
Research Areas:
Infection Neurological Disease Inflammation/Immunology Cancer
Doxycycline hydrochloride (Standard) is the analytical standard of Doxycycline hydrochloride (HY-N0565A). This product is intended for research and analytical applications. Doxycycline hydrochloride is an orally active highly lipophilic, tissue-permeable MMP inhibitor with broad-spectrum antibacterial activity. Doxycycline hydrochloride is also a semi-synthetic antibiotic with chelating properties, which blocks bacterial protein synthesis and inhibits extracellular matrix degradation through interactions with zinc and calcium atoms. Doxycycline hydrochloride also inhibits mitochondrial biogenesis, translation, and the expression of respiratory chain proteins. Doxycycline hydrochloride induces apoptosis, inhibits autophagy and EMT, downregulates stem cell markers, and activates the PI3K-AKT pathway, thereby effectively inhibiting the viability and proliferation of cancer cells such as breast cancer cells. Doxycycline hydrochloride also promotes the survival and self-renewal of embryonic stem cells and neural stem cells, and reduces the frequency of medium changes in culture. Doxycycline hydrochloride has been applied in studies related to breast cancer, prostate cancer, bladder cancer, and other cancers .
Cat. No.: HY-N0565AS
Research Areas:
Infection Neurological Disease Inflammation/Immunology Cancer
Doxycycline (Standard) is the analytical standard of Doxycycline (HY-N0565). This product is intended for research and analytical applications. Doxycycline is an orally active highly lipophilic, tissue-permeable MMP inhibitor with broad-spectrum antibacterial activity. Doxycycline is also a semi-synthetic antibiotic with chelating properties, which blocks bacterial protein synthesis and inhibits extracellular matrix degradation through interactions with zinc and calcium atoms. Doxycycline also inhibits mitochondrial biogenesis, translation, and the expression of respiratory chain proteins. Doxycycline induces apoptosis, inhibits autophagy and EMT, downregulates stem cell markers, and activates the PI3K-AKT pathway, thereby effectively inhibiting the viability and proliferation of cancer cells such as breast cancer cells. Doxycycline also promotes the survival and self-renewal of embryonic stem cells and neural stem cells, and reduces the frequency of medium changes in culture. Doxycycline has been applied in studies related to breast cancer, prostate cancer, bladder cancer, and other cancers .
Cat. No.: HY-N0565S3
CAS No.: 1902958-13-7
Cat. No.: HY-W013724
CAS No.: 54735-61-4
Synonyms: IDP disodium; Inosine-5'-diphosphoric acid disodium
Research Areas:
Inosine-5'-diphosphate disodium (IDP disodium) is a decoy substrate of NM23-H2. Inosine-5'-diphosphate disodium has a superior bond capacity on GDP-binding pocket of NM23-H2 (KD: 5.0 μM). Inosine-5'-diphosphate disodium abrogates c-MYC transcription, induces apoptosis and G2/M cell cycle arrest by disrupting NM23-H2-Pu27-GQ interactions without affecting NM23-H2-mediated kinase properties. Inosine-5'-diphosphate disodium has antihypoxic, antihyperthermic and antiarrhythmic activity and protects animals against the noxious effects of γ-irradiation. Inosine-5'-diphosphate disodium can be used for cancers like Burkitt's lymphoma and cardiovascular diseases research .
Cat. No.: HY-W714524
CAS No.: 321863-21-2
Synonyms: 16:0-18:1 PS (POPS)
Target:
Research Areas:
1-Palmitoyl-2-oleoyl-sn-glycero-3-PS sodium (16:0-18:1 PS (POPS)) is an anionic phosphatidylserine phospholipid with 16:0 (palmitoyl) and 18:1 (oleoyl) acyl chains. It serves as a component of biomimetic inner plasma membrane models and membrane vesicles for hemostatic response studies. 1-Palmitoyl-2-oleoyl-sn-glycero-3-PS sodium regulates membrane electrical properties by forming tethered bilayer lipid membranes. It enhances the stability of sHDL particles without altering the cholesterol efflux capacity of sHDL. 1-Palmitoyl-2-oleoyl-sn-glycero-3-PS sodium acts synergistically with phosphatidylcholine to support prothrombin activation. It serves as a component of the 4:1 POPC/POPS binary lipid bilayer model. 1-Palmitoyl-2-oleoyl-sn-glycero-3-PS sodium is applicable to research related to atherosclerosis .
Cat. No.: HY-W766368
Synonyms: C6-Cer-13C2,d2; N-Hexanoylsphingosine-13C2,d2
Target:
Research Areas:
C6 Ceramide- 13C2,d2 (C6-Cer- 13C2,d2) is the deuterium labeled and 13C-labeled C6 Ceramide (HY-19542). C6 Ceramide (C6-Cer) is a short-chain, cell-permeable ceramide pathway activator with anticancer activity. C6 Ceramide-mediated miR-29b expression participates in the progression of multiple myeloma through suppressing the proliferation, migration and angiogenesis of endothelial cells by targeting Akt signal pathway. C6 Ceramide exhibits multiple anti-cancer properties including cell cycle arrest, Apoptosis, inhibition of tumor growth and enhances the effects of chemotherapy in drug-resistant cancer cells. C6-ceramide can be used as an adjuvant for chemotherapeutic agents, to enhance anti-tumor effects .
Cat. No.: HY-L942
1,626 compounds
Unlike highly conserved orthosteric sites, allosteric sites exhibit low conservation, high hydrophobicity, weak polarity, confined geometry, and dynamic cryptic properties. Rather than rigid keyhole-like cavities, they typically appear as flexible grooves, subunit interface clefts, or shallow depressions formed by protein conformational changes.
Based on the dynamic, hydrophobic, and elongated nature of allosteric pockets, MCE has carried out targeted fragment modification and screening under strict physicochemical criteria: MW 120–280 Da, HBD ≤ 2, HBA ≤ 3, PSA 30–80 Ų, rotatable bonds ≤ 2, cLogP 1–3.5. High 3D diversity was further ensured by PMI analysis, yielding fragments with excellent shape complementarity to allosteric pockets.
This library contains 1,800 structurally diverse, drug-like fragments, this library supports allosteric drug development and pocket optimization. It significantly improves screening hit rates and enables efficient, precise early-stage R&D of allosteric drugs.
Cat. No.: HY-L200
2,818 compounds
Natural products are small molecular compounds that occur in nature and come from any organism, including primary and secondary metabolites. Natural products have potential biological activity and can be used as lead compounds for drug discovery. Nature has been a source of medicines for thousands of years, and a large number of drugs have been isolated from nature, many based on their use in traditional medicine. With the development of compound targets, there is an increasing need to screen for compound diversity. Through ongoing research into natural biodiversity, much of which remains to be exploited, natural products will play a key role in meeting this demand. The Lipinski rule of 5 is used to describe the drug-like properties of a molecule, molecules that adhere to the rule of 5 have higher drug potential. Based on MCE natural product library, MCE selects the molecules that obey the rule of 5, which makes the efficiency of drug screening higher.
MCE designs a unique collection of 2,818 RO5 drug-like natural products, which is an important tool for drug discovery.
Cat. No.: HY-L257
0 compounds
Linkers, as key structural units in PROTAC molecules that connect the two functional ends, not only determine the overall molecular conformation and spatial compatibility but also directly influence the stability of the ternary complex, as well as cellular permeability and degradation efficiency. In recent years, with the widespread application of click chemistry in medicinal chemistry, the incorporation of bioorthogonal reactive groups such as azides (-N3) into PROTAC linker design has become an emerging research focus, providing an important tool for modular assembly and rapid structural optimization.
The MCE Azide PROTAC Linker Library contains 0 linkers specifically designed for targeted protein degradation molecule design and optimization. These linkers serve as efficient “click handles,” enabling rapid and highly selective covalent coupling with alkyne reaction partners, thereby facilitating modular assembly and structural diversification of PROTAC molecules. In drug development, this design not only improves the efficiency of molecular construction but also significantly accelerates the screening and optimization of lead compounds. Meanwhile, by tuning linker properties such as length, flexibility, and polarity, the ability to form ternary complexes and degradation activity can be optimized.
Cat. No.: HY-L053
1,534 compounds
From target identification to clinical research, traditional drug discovery and development is a time-consuming and costly process, which also bears high risk. Compared with traditional drug discovery, drug repositioning or repurposing, also known as old drugs for new uses can greatly shorten the development cycle and reduce development cost, which has become a new trend of drug development. After undergoing clinical trials, approved drugs have identified bioactivities, good pharmacokinetic characteristics and safety, which can greatly improve the success rate of drug discovery. A number of successes have been achieved, such as metformin for type 2 diabetes and thalidomide for leprosy and multiple myeloma, etc.
MCE provides a unique collection of 1,534 China NMPA (National Medical Products Administration) approved compounds, which have undergone extensive preclinical and clinical studies and have well-characterized bioactivities, safety and bioavailability properties. MCE NMPA-Approved Drug Library is a good tool for drug repurposing which could dramatically accelerate drug development.
Cat. No.: HY-112624H
CAS No.: 9004-54-0
Synonyms: Dextran 2; Dextran D2; Dextran T2(MW 1600-2400)
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
